Answers are grounded in this paper and cite their sources.
This research demonstrates the effectiveness of GLP-1 and dual GIP/GLP-1 receptor agonists in treating inflammatory skin diseases, highlighting the need for ongoing lifestyle support.
GLP-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 RAs show promise for managing obesity-associated inflammatory skin diseases, including psoriasis and hidradenitis suppurativa. However, treatment discontinuation often leads to rapid weight regain and reversal of metabolic improvements, raising concerns about potential relapse of skin disease. Behavioural modification remains essential for maintaining therapeutic gains, and clinicians should prioritise structured lifestyle support, patient education, and ongoing monitoring alongside pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: